A Study to Compare Pharmacokinetics of GB1211

Pharmacokinetics Clinical Trial

Official title:

An Open-label, Randomized, Three-period, Crossover Study to Compare the Pharmacokinetics of GB1211 Upon Dosing a Capsule Under Fasting Condition and a Tablet Under Fasting and Fed Conditions in Healthy Volunteers

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05747573
• Other study ID #: GALBA-1
• Secondary ID: GB1211-CPH-005
• Status: Completed
• Phase: Phase 1
• Start date: January 3, 2023
• Est. completion date: April 10, 2023

Study information

• Verified date: February 2023
• Source: Galecto Biotech AB
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is an open label, Randomized, Three-period, Crossover Study to Compare the Pharmacokinetics of GB1211 upon Dosing a Capsule under Fasting Condition and a Tablet under Fasting and Fed Conditions in Healthy Volunteers

Description:

This is relative bioavailability and food effect study to enable further clinical development of a tablet formulation of GB1211.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 13
• Est. completion date: April 10, 2023
• Est. primary completion date: April 10, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

1. Subjects must provide written informed consent prior to any Screening procedures being performed.

2. Male and female subjects 18-55 years of age (inclusive) on the day of signing the informed consent.

3. Subjects deemed in good physical health by the Investigator, as determined by no clinically significant findings from medical history, laboratory safety tests (serology, hematology, biochemistry and urinalysis), physical examination, vital signs, and electrocardiogram (ECG).

4. Women of child-bearing potential (WOCP) must agree not to attempt to become pregnant or donate ova, and to use a highly effective form of hormonal or non-hormonal birth control during the study and for 180 days after the last study drug administration, including:

• combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation:

• oral

• intravaginal

• transdermal

• progestogen-only hormonal contraception associated with inhibition of ovulation:

• oral

• injectable

• implantable

• intrauterine device (IUD)

• intrauterine hormone-releasing system (IUS)

• bilateral tubal occlusion

• vasectomized partner

• sexual abstinence

5. Postmenopausal women must have had =12 months of spontaneous amenorrhea (with documented follicle-stimulating hormone (FSH) =30 mIU/mL). Surgically sterile women are defined as those who have had a hysterectomy, bilateral ovariectomy, or bilateral tubal ligation. Women who are surgically sterile must provide documentation of the procedure.

6. Sexually active male subjects must use a barrier method of contraception (condom) and refrain from sperm donation during the study and for at least 90 days after the last study drug administration if their female sexual partner is of childbearing potential. Acceptable methods of birth control for female partners of male subjects are: hormonal contraceptives (oral contraceptives, implant or injection), intrauterine device (placed at least 1 month before the start of the study). Surgical sterilization of male patients can be accepted as a form of birth control if the sterilization procedure took place at least 6 months prior to the start of the study.

7. Adequate venous access for blood sampling.

8. Body mass index (BMI) between 18.0 to 32.0 kg/m2 (inclusive) at Screening.

9. Body temperature between 35.5-37.5 ºC (inclusive) at Screening and on Day -1 of Study Period 1.

10. Subjects agree to be available for the entire duration of the study and to be able to adhere to the study restrictions and examination schedule.

11. Able to swallow medication.

12. Subjects must be able to communicate well with the investigator and to comply with the requirements of the entire study.

Exclusion Criteria:

1. Contraindication or hypersensitivity to any drug or metabolites from similar class as study drug or to any excipients of the study drug formulation (including lactose).

2. Donation of 400 mL or more of blood or plasma within 8 weeks prior to first dosing.

3. Receipt of an investigational product within 90 days prior to the first dose of study drug.

4. History or presence of clinically significant ECG abnormalities or a family history or presence of prolonged QT-interval syndrome. Screening or Day -1 of Study Period 1 ECG: QTcF >450msec; PR >210 msec; QRS complex >119 msec, or other morphological changes other than repolarization, nonspecific S-T or T-wave changes.

5. Abnormal vital signs, after 5 minutes supine rest at Screening or on Day -1 of Study Period 1, defined as any of the following:

1. Systolic blood pressure of < 90 or > 140 mmHg

2. Diastolic blood pressure of < 45 or > 90 mmHg

3. Pulse rate < 40 or > 100 bpm One (1) re-test may be performed at Screening and Day -1 of Study Period 1.

6. History of cardiac disease such as:

1. Presence of clinically significant ventricular or atrial arrhythmia;

2. History of clinically documented myocardial infarction;

3. History of unstable angina pectoris;

4. Other clinically significant cardiovascular disease (e.g., congestive heart failure).

7. Any positive result at Screening for serum hepatitis B surface antigen, hepatitis C antibody, and human immunodeficiency virus (HIV), and on Day -1 for COVID-19.

8. Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of drugs. The investigator is to be guided by evidence of any of the following: history of major gastrointestinal surgery such as gastrectomy, gastroenterostomy, bowel resection or cholecystectomy. Subjects with a history of appendectomy are eligible to participate.

9. History of psychiatric illness within the past 2 years that may interfere with the ability to comply with the protocol requirements.

10. History of malignancy of any organ system (other than localized basal cell carcinoma of the skin or in situ cervical cancer), treated or untreated, within 5 years, regardless of whether there is recurrence or metastases.

11. Smokers (use of tobacco or nicotine-containing products in the previous 3 months) and not willing to abstain from using tobacco or nicotine-containing products during the study. Positive cotinine test results at Screening or Day -1 are reason for exclusion. One (1) cotinine re-test may be performed at Screening and on Day -1 for otherwise eligible subjects who were recently exposed to passive smoke inhalation.

12. History of drug or alcohol abuse within 12 months prior to first dose and/or a positive urine drug screen/alcohol breath test at Screening or Day -1 of Study Period 1.

13. Use of any prescription or non-prescription medication including vaccination (excluding paracetamol, hormonal contraceptives), herbal medication, dietary supplements, or vitamins within 14 days prior to first dosing.

14. Administration of CYP3A4/5 inhibitors or inducers within 4 weeks prior to first dosing.

15. Administration of P-gp inhibitors or inducers within 4 weeks prior to first dosing.

16. Administration of medications that prolong the QT interval within 4 weeks prior to first dosing.

17. A positive pregnancy test at Screening or Day -1 of Study Period 1 or lactation.

18. Potentially unreliable or vulnerable subjects (e.g., person kept in detention) and those judged by the investigator to be unsuitable for the study.

Related Conditions & MeSH terms

• Pharmacokinetics

Intervention

Drug:
• GB1211
Hard tablet or capsules for oral use

Locations

Country	Name	City	State
Netherlands	QPS Netherlands BV	Groningen

Sponsors (2)

Lead Sponsor	Collaborator
Galecto Biotech AB	QPS Holdings LLC

Country where clinical trial is conducted

Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	To determine the relative abundance of GB1211 metabolites in plasma and in urine	Plasma samples: Period 1: Day 1: pre-dose and at hrs 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24 (Day 2), 48 (Day 3), 72 (Day 4), and 96 (Day 5) post-dose.; Period 2: Day 1: pre-dose and at 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24 (Day 2), 48 (Day 3), 72 (Day 4), and 96 (Day 5) post-dose.; Period 3: Day 1: pre-dose and at 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24 (Day 2), 48 (Day 3), 72 (Day 4), and 96 (Day 5) post-dose.; Urine samples: Study Period 1: Pre-dose (single sample) and at [0 to 6 h], [6 to 12 h] (Day 1), [12 to 24 h] (Day 2), [24 to 48 h] (Day 3), [48 to 72 h] (Day 4), [72 to 96 h] (Day 5) post-dose.	5 weeks
Primary	To measure the maximum plasma concentration of GB1211 (Cmax)	Timepoints for PK sampling; Period 1: Day 1: pre-dose and at hrs 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24 (Day 2), 48 (Day 3), 72 (Day 4), and 96 (Day 5) post-dose.; Period 2: Day 1: pre-dose and at 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24 (Day 2), 48 (Day 3), 72 (Day 4), and 96 (Day 5) post-dose.; Period 3: Day 1: pre-dose and at 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24 (Day 2), 48 (Day 3), 72 (Day 4), and 96 (Day 5) post-dose.	5 weeks
Primary	To measure the time to reach Cmax GB1211 (Tmax)	Timepoints for PK sampling; Period 1: Day 1: pre-dose and at hrs 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24 (Day 2), 48 (Day 3), 72 (Day 4), and 96 (Day 5) post-dose.; Period 2: Day 1: pre-dose and at 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24 (Day 2), 48 (Day 3), 72 (Day 4), and 96 (Day 5) post-dose.; Period 3: Day 1: pre-dose and at 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24 (Day 2), 48 (Day 3), 72 (Day 4), and 96 (Day 5) post-dose.	5 weeks
Primary	To measure the area under the plasma concentration-time curve of GB1211 (AUC)	Timepoints for PK sampling for; Period 1: Day 1: pre-dose and at hrs 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24 (Day 2), 48 (Day 3), 72 (Day 4), and 96 (Day 5) post-dose.; Period 2: Day 1: pre-dose and at 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24 (Day 2), 48 (Day 3), 72 (Day 4), and 96 (Day 5) post-dose.; Period 3: Day 1: pre-dose and at 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24 (Day 2), 48 (Day 3), 72 (Day 4), and 96 (Day 5) post-dose.	5 weeks
Primary	To measure the amount of GB1211 excreted in urine (Ae)	Study Period 1: Pre-dose (single sample) and at [0 to 6 h], [6 to 12 h] (Day 1), [12 to 24 h] (Day 2), [24 to 48 h] (Day 3), [48 to 72 h] (Day 4), [72 to 96 h] (Day 5) post-dose.	5 days
Primary	To measure the fraction of GB1211 excreted in urine (Fe)	Study Period 1: Pre-dose (single sample) and at [0 to 6 h], [6 to 12 h] (Day 1), [12 to 24 h] (Day 2), [24 to 48 h] (Day 3), [48 to 72 h] (Day 4), [72 to 96 h] (Day 5) post-dose.	5 days
Secondary	To determine the number of participants with adverse events	Number of participants with adverse events graded as mild, moderate, or severe according to the study protocol.; Number of participants with adverse events related and not related to the study drug.	5 weeks